Phase III trial of TAS 102 for Colorectal Cancer meets primary endpoint - Taiho Pharma
Taiho Pharmaceutical announced results from its global Phase III RECOURSE trial on its oral combination anticancer drug TAS 102 (trifluridine and tipiracil hydrochloride) in refractory metastatic Colorectal Cancer (mCRC). The RECOURSE trial met its primary endpoint of demonstrating improvement in overall survival (OS) in patients with refractory mCRC whose disease had progressed after approved standard therapies.
In this trial, TAS 102 appeared to be generally well tolerated and the toxicities were consistent with what was previously reported. More detailed results from the RECOURSE trial will be presented during the ESMO 16th World Congress on Gastrointestinal Cancer.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.